X

Trial Profile

A Randomized Controlled Trial Comparing the Safety and Efficacy of IDegLira Versus Basal Bolus in Patients With Poorly Controlled Type 2 Diabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin degludec/liraglutide (Primary) ; Insulin aspart; Insulin degludec; Metformin
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms DUAL HIGH; IDegLira HIGH Trial

Most Recent Events

17 Jul 2023 Primary endpoint has been met. (Change in Hemoglobin A1c (HbA1c), as per Results published in the Diabetes Care
17 Jul 2023 Results published in the Diabetes Care
04 Aug 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com